LS
LSTA.BEL
—
—
Pharmaceuticals & Medical Research
Lasta A.d. Beograd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-11,8 %
ROE
-97,9 %
Net margin
-21,1 %
Debt / equity
2,39
Beta
—
52w range
—
Volume
2
Day range
—
Prev close
$3,30
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Lasta A.d. Beograd operates in the Ground Transportation industry within the Industrials sector, generating revenue through transportation services, though specific operational details are unclassified.
Business. Lasta A.d. Beograd operates in the Ground Transportation industry within the Industrials sector, generating revenue through transportation services, though specific operational details are unclassified.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target11,33
Analyst recommendations
3 analysts · consensus BuyBuy3
Hold0
Sell0
12-month price target
11,33
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
-97,9 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to LSTA.BEL. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Lasta A.d. Beograd operates in the Ground Transportation industry within the Industrials sector, generating revenue through transportation services, though specific operational details are unclassified.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATED— missing data
Key takeaways
- The company faces critical liquidity constraints with a current ratio of 0.18 and minimal cash reserves of 25.15 million RSD.
- High leverage is evident with a debt-to-equity ratio of 2.39 and total liabilities exceeding total assets' equity portion significantly.
- Profitability is severely impaired with a net income loss of 1.42 billion RSD and negative returns on equity (-0.979) and assets (-0.1414).
- Free cash flow is negative at -926.15 million RSD, indicating an inability to generate cash after capital expenditures.
- Dilution risk is assessed as low, but the negative net cash position poses a significant solvency threat.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$665,00
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$1.45B
Net cashⓘ
-$3.44B
Current ratioⓘ
0.2
Debt / equityⓘ
2.4
ROAⓘ
-14.1%
ROEⓘ
-97.9%
Cash conversionⓘ
-13.0%
CapEx / revenueⓘ
-1.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
NGL & Refined Products Transportation—
low · llm_fanout_v2
Passenger & Cargo Handling—
low · llm_fanout_v2
Transportation—
low · llm_fanout_v2
Business relationships
Business relationships7 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries7
EX21:0d697e99e830EX21:0d697e99e830Subsidiarie97%
EX21:48f7b2962e61EX21:48f7b2962e61Subsidiarie97%
EX21:6ad276361b71EX21:6ad276361b71Subsidiarie97%
EX21:84a348b7fc0eEX21:84a348b7fc0eSubsidiarie97%
EX21:bca3685fea8aEX21:bca3685fea8aSubsidiarie97%
EX21:cb5a1f8bf226EX21:cb5a1f8bf226Subsidiarie97%
EX21:d5ba48d557fbEX21:d5ba48d557fbSubsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs LSTA · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+53,0 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
-35,3 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-147,6 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+17,6 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+31,5 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
-44,9 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,96
Predicted surprise
+0,00
Beat probability
45 %
Analysts
3
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,00
Mean$11,33
Median$15,00
High$15,00
Spot$665,00
−98.3 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-11,8 %Above P75
Net Margin-21,1 %Above P75
ROE-97,9 %Bottom quartile
Capex / Rev-1,6 %Below median
D/E2,39Bottom quartile
Cash Conv-0,13Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 67 000 sh4 grants4 insiders
- Director, President & CEO · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $1,97grant · 2026-01-09
- SVP, Fin/Treas, Chief Actg Off · Stock Option (Right to Buy) → Common StockAcquired 7 000 @ $1,97grant · 2026-01-09
- SVP, Bus Dev, General Counsel · Stock Option (Right to Buy) → Common StockAcquired 7 000 @ $1,97grant · 2026-01-09
- EVP, R&D and CMO · Stock Option (Right to Buy) → Common StockAcquired 13 000 @ $1,97grant · 2026-01-09
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Return On Assetsnet_income / total_assets
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- Lasta A.d. Beograd Market data — financials · 2026-07-06
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d
- Director, President & CEO · Common StockOther 10 515 @ $1,97$21K · 2026-01-09
- Director, President & CEO · Common StockOther 12 224 @ $1,97$24K · 2026-01-09
- Director, President & CEO · Common StockOther 7 854 @ $1,97$15K · 2026-01-09
- SVP, Fin/Treas, Chief Actg Off · Common StockOther 15 000 · 2026-01-09
- SVP, Fin/Treas, Chief Actg Off · Common StockOther 2 131 @ $1,97$4K · 2026-01-09
- SVP, Fin/Treas, Chief Actg Off · Common StockOther 1 137 @ $1,97$2K · 2026-01-09
- SVP, Fin/Treas, Chief Actg Off · Common StockOther 781 @ $1,97$2K · 2026-01-09
- SVP, Bus Dev, General Counsel · Common StockOther 15 000 · 2026-01-09
- SVP, Bus Dev, General Counsel · Common StockOther 1 401 @ $1,97$3K · 2026-01-09
- SVP, Bus Dev, General Counsel · Common StockOther 840 @ $1,97$2K · 2026-01-09
- SVP, Bus Dev, General Counsel · Common StockOther 747 @ $1,97$1K · 2026-01-09
- SVP, Bus Dev, General Counsel · Common StockOther 513 @ $1,97$1K · 2026-01-09
- EVP, R&D and CMO · Common StockOther 25 000 · 2026-01-09
- EVP, R&D and CMO · Common StockOther 2 982 @ $1,97$6K · 2026-01-09
- EVP, R&D and CMO · Common StockOther 3 221 @ $1,97$6K · 2026-01-09
- EVP, R&D and CMO · Common StockOther 2 147 @ $1,97$4K · 2026-01-09
- Director · Common StockOther 30 456 · 2026-01-09
- Director · Common StockOther 30 456 · 2026-01-09
- Director · Common StockOther 30 456 · 2026-01-09
- Director · Common StockOther 30 456 · 2026-01-09
- Director · Common StockOther 30 456 · 2026-01-09
- Director, President & CEO · Common StockOther 81 000 · 2026-01-09
- Director, President & CEO · Common StockOther 10 503 @ $1,97$21K · 2026-01-09
Short positioning
129.9Kshares short+24.0% vs prior
2.81days to cover
49.1%short of daily vol
24.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
LSTA.BELCanonical
— · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): -49.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -83.0%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -44.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -49.8%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 18.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 17.6%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 17.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 20.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 20.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.21xDerived (calculated)
- Current ratio (FY 2025-12-31): 5.76xDerived (calculated)
- Return on assets (FY 2025-12-31): -93.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -111.7%Derived (calculated)
- Net margin (FY 2025-12-31): -9,756.5%Derived (calculated)
- EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
- Total assets (annual): USD 17.74MSEC XBRL filing
- Total operating expenses (annual): USD 18.38MSEC XBRL filing
- Operating income (annual): USD -18.21MSEC XBRL filing
- Net income (annual): USD -16.59MSEC XBRL filing
- Pre-tax income (annual): USD -17.55MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
- Operating cash flow (annual): USD -15.95MSEC XBRL filing
- Revenue (annual): USD 170KSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-01-09 00:00 UTCINSIDER27 insider transactions — 2026-01 · net sell $112k 4 derivative
2026-01-09INSIDERMazzo David J transacted 10.5k sh — Director, President & CEO ~$21k
2026-01-09INSIDERMazzo David J transacted 12.2k sh — Director, President & CEO ~$24k
2026-01-09INSIDERMazzo David J transacted 7.9k sh — Director, President & CEO ~$15k
2026-01-09INSIDERNisco James transacted 15.0k sh — SVP, Fin/Treas, Chief Actg Off
2026-01-09INSIDERNisco James transacted 2.1k sh — SVP, Fin/Treas, Chief Actg Off ~$4k
2026-01-09INSIDERNisco James transacted 1.1k sh — SVP, Fin/Treas, Chief Actg Off ~$2k
2026-01-09INSIDERNisco James transacted 781 sh — SVP, Fin/Treas, Chief Actg Off ~$2k
2026-01-09INSIDERImam Tariq transacted 15.0k sh — SVP, Bus Dev, General Counsel
2026-01-09INSIDERImam Tariq transacted 1.4k sh — SVP, Bus Dev, General Counsel ~$3k
2026-01-09INSIDERImam Tariq transacted 840 sh — SVP, Bus Dev, General Counsel ~$2k
2026-01-09INSIDERImam Tariq transacted 747 sh — SVP, Bus Dev, General Counsel ~$1k
2026-01-09INSIDERImam Tariq transacted 513 sh — SVP, Bus Dev, General Counsel ~$1k
2026-01-09INSIDERBuck Kristen K transacted 25.0k sh — EVP, R&D and CMO
2026-01-09INSIDERBuck Kristen K transacted 3.0k sh — EVP, R&D and CMO ~$6k
2026-01-09INSIDERBuck Kristen K transacted 3.2k sh — EVP, R&D and CMO ~$6k
2026-01-09INSIDERBuck Kristen K transacted 2.1k sh — EVP, R&D and CMO ~$4k
2026-01-09INSIDERKLOSK STEVEN M transacted 30.5k sh — Director
Showing the 40 most recent of 53 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage